Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical NK Cells with IL-15 for AML
NCT02395822Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Oct 2015
- Primary completion
- Dec 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human interleukin-15 in acute myeloid leukemia (AML), sponsored by Masonic Cancer Center. Started Oct 2015; status: completed.
02
Drugs
recombinant human interleukin-15
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02395822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02395822.